Retrospective clinical analysis of 133 cases of stage Ⅳ esophageal cancer
10.3760/cma.j.issn.1004-4221.2020.02.005
- VernacularTitle: 133例Ⅳ期食管癌的临床回顾性分析
- Author:
Junjun GUO
1
;
Wei GAO
2
;
Qian WANG
1
;
Shenbo FU
1
;
Pan XI
1
Author Information
1. Department of Radiation Oncology, Shaanxi Provincial Cancer Hospital, Xi′an 710061, Shaanxi, China
2. Department of Thoracic Surgery, Shaanxi Provincial Cancer Hospital, Xi′an 710061, Shaanxi, China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasm/radiochemotherapy;
Esophageal neoplasm/chemotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2020;29(2):102-105
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.
Methods:Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model.
Results:The 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P<0.05). The 1-, 2-and 3-year survival rates in the radiochemotherapy group were 61%, 29% and19%, and 40%, 4%, 0% in the chemotherapy group, respectively. In the radiochemotherapy group, the progression-free survival (PFS) and local progression-free survival (LPFS) were 8 months and 12.6 months, significantly longer compared with 4.7 months and 5.3 months in the chemotherapy group (both P<0.05). The OS of patients receiving dose> 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05).
Conclusion:Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.
